IceCure Medical (NASDAQ:ICCM) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of IceCure Medical (NASDAQ:ICCM – Free Report) from a hold rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

A number of other research analysts also recently issued reports on the stock. Zacks Research downgraded shares of IceCure Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, August 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $52.50.

Get IceCure Medical alerts:

Get Our Latest Stock Report on IceCure Medical

IceCure Medical Stock Performance

NASDAQ:ICCM opened at $1.96 on Friday. The company has a market cap of $6.72 million, a price-to-earnings ratio of -0.23 and a beta of 0.45. The stock’s fifty day moving average price is $2.73 and its two-hundred day moving average price is $7.07. IceCure Medical has a 52-week low of $1.95 and a 52-week high of $42.00.

IceCure Medical (NASDAQ:ICCM – Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share for the quarter. The firm had revenue of $0.91 million for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%. On average, equities analysts predict that IceCure Medical will post -4.61 EPS for the current fiscal year.

IceCure Medical Company Profile

(Get Free Report)

IceCure Medical Ltd. is an Israel-based medical device company that develops minimally invasive cryoablation technology for the treatment of tumors. The company’s technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to more invasive surgical procedures.

Its primary product, the ProSense system, is designed to deliver controlled cryoablation through a thin probe inserted into a tumor under image guidance. The system has been developed for use in a range of tumor types, including breast, kidney, liver, lung and bone tumors, and has received regulatory clearances and approvals for certain indications in markets including the United States and other countries.

IceCure Medical is headquartered in Caesarea, Israel, and serves healthcare providers through commercial and distribution activities in international markets, including North America, Europe and Asia.

See Also

• Five stocks we like better than IceCure Medical
• Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
• Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
• These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
• Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike

Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.